Compare BioNano Genomics Inc (BNGO) vs Harmony Gold Mining Co. (HMY) Price & Performance

Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.

BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.

Harmony Gold Mining (HMY) trades at $14.99, down 0.79% on the day, with a bearish technical signal from moving averages. The company shows strong fundamentals with 2024 revenue of $61.38 billion and net income of $8.59 billion, yielding robust profitability margins. Recent earnings were mixed, beating in Q2 2025 but missing in Q4 2025. Analyst sentiment is cautious with 70% hold ratings, while news highlights stock volatility tied to gold price sensitivity and Fed policy expectations.

HMY presents a valuation opportunity with low P/E (9.59) and EV/EBITDA (5.05) multiples, supported by high ROE (32.32%) and a 4.06% dividend yield. Key risks include gold price exposure, operational execution in its pivot to gold-copper hybrid model, and macroeconomic headwinds from potential interest rate hikes. Institutional consensus leans neutral, suggesting patience for copper project contributions to justify higher multiples.